6 researched Healthtech entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer To hire a fractional CRO for a healthtech business, define the specific revenue problem you need solved (pipeline, GTM motion, payer contracting, or a raise), then source operators who have carried a quota inside regulated hea…
Read full answer ↗Direct Answer Pear Therapeutics needed to abandon the standalone prescription model and pivot to embedded distribution by locking payer contracts before launch, narrowing to one indication, and plugging into PBM infrastructure like CVS to e…
Read full answer ↗Direct Answer 23andMe's 2026 turnaround pivots from DTC-only consumer genetics to a B2B therapeutics + data monetization hybrid model, fixing the broken one-time-kit CAC problem by: (1) ruthless cost discipline post-Regeneron acquisition, (…
Read full answer ↗Direct Answer Cedar's 2026 revenue problem isn't the product—it's margin erosion from uninsured-patient mix shift. The fix: shrink difficult-to-collect cohorts with propensity-pay targeting, bundle OODA payer data to unlock step-down rates …
Read full answer ↗Direct Answer Olive's 2026 resurrection requires surgical focus: abandon horizontal RCM-for-everyone, build a vertical-first play for one hospital network type (health systems under 100 beds), drop 80% of the feature matrix, ship agentic RP…
Read full answer ↗Direct Answer A 2026 Forward reboot survives by abandoning the $1M/pod hardware play, pivoting to a hybrid model: Concierge DPC (premium) + insurance-backed partnerships (volume) + AI-native triage (margin), with ruthless unit economics and…
Read full answer ↗